Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Haley Neff-LaFord"'
Autor:
Priyanka Gupta, Haley Neff-LaFord, Kelly Hensley, Sean Allred, Andres Forero-Torres, Byron Kwan, Megan Ramirez, Steven Jin, Changpu Yu, Serena Wo, Jessica Simmons, Christina Zuch de Zafra, Shawna Hengel, Heather Van Epps
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/5b55852b95754d28bcc8588ebe7f1c9a
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/da855c2eba5046209c813624db008aad
Autor:
Ignace Vergote, Stella Kim, Paul Ursell, Sandro Pignata, Antonio Gonzalez-Martin, Leslie Randall, Bohuslav Melichar, Kristine Madsen, Sven Mahner, Domenica Lorusso, Stéphanie Henry, Lydia Gaba, Theodora Salcedo, Haley Neff-Laford, Jeffrey Harris, Joy Jiang, Ibrahima Soumaoro, Shweta Jain, Bradley Monk, Robert L Coleman
Publikováno v:
E-Posters.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e203d0914a05e695cd7b8fa5e2ec7ba4
https://doi.org/10.1136/ijgc-2022-igcs.155
https://doi.org/10.1136/ijgc-2022-igcs.155
Autor:
Matthew Levengood, Chris Leiske, Noah Bindman, Xinqun Zhang, Nicole Duncan, Weiping Zeng, Serena Wo, Abbie Wong, Clark Henderson, Karalyne Crowder, Haley Neff-LaFord, Django Sussman, Shyra Gardai, Philip Moquist
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca16c591e415cb65eb959c058004bae0
https://doi.org/10.1136/jitc-2022-sitc2022.1357
https://doi.org/10.1136/jitc-2022-sitc2022.1357
Autor:
Gabriela Patilea-Vrana, John Harrold, Joseph A. Ware, Shaparak Lonning, Hun Lee, Lisa Brooks, Haley Neff-LaFord, William D. Hanley, Andres Forero-Torres
Publikováno v:
Cancer Research. 83:5668-5668
SEA-TGT is a human nonfucosylated monoclonal antibody (mAb) targeting the T cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) protein. TIGIT is an immunoregulatory receptor expressed on activated and memory T cells, Tregs, and NK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8b613c984363f3123e23e367f559075
https://doi.org/10.1158/1538-7445.am2023-5668
https://doi.org/10.1158/1538-7445.am2023-5668
Autor:
Steven Jin, Shawna Hengel, Christina L. Zuch de Zafra, Byron Hua Kwan, Sean Allred, Andres Forero-Torres, Megan Ramirez, Haley Neff-LaFord, Changpu Yu, Serena Wo, Jessica K. Simmons, Heather Van Epps, Priyanka Gupta, Kelly Hensley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPD-1/PD-L1 immune checkpoint inhibitors have transformed oncology, but a significant unmet need persists for patients with relapsed/refractory tumors following PD-1/PD-L1 treatment. PD-L1 is expressed in patients across a broad spectrum of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf5354dce62227e2df08699edde794af
https://doaj.org/article/5b55852b95754d28bcc8588ebe7f1c9a
https://doaj.org/article/5b55852b95754d28bcc8588ebe7f1c9a
Autor:
Olivier Rixe, Timothy M. Kuzel, David Smith, Martin Gutierrez, Sahar Ansari, John A. Thompson, Sanjay Goel, Andrew L. Coveler, Michael W. Schmitt, Thomas F. Gajewski, David L. Bajor, Haley Neff-LaFord, Shyra Gardai, Elisabeth I. Heath, Brendan D. Curti, Svetomir N. Markovic, Celine Jacquemont, Juneko E. Grilley-Olson
Publikováno v:
Cancer Research. 80:5535-5535
CD40 is a co-stimulatory receptor of the TNF receptor superfamily expressed on antigen presenting cells (APCs). Antibodies targeting CD40 may have therapeutic benefit via multiple mechanisms including innate immune activation that can support generat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8353786ba7b8a40d1cfe65deddd99b39
https://doi.org/10.1158/1538-7445.am2020-5535
https://doi.org/10.1158/1538-7445.am2020-5535
Autor:
Wendi Schultz, Cindy Balasubramanian, Paul Pittmen, Shawna Hengel, Nagendra Chemuturi, Franciso Zapata, Jocelyn R. Setter, Russell J. Sanderson, Haley Neff-LaFord, Robert P. Lyon
Publikováno v:
Cancer Research. 77:70-70
Antibody-drug conjugates (ADCs) continue to emerge as effective therapeutics in a variety of oncology indications, with two agents currently approved and many more in late-stage clinical trials. These ADCs employ drug-linkers that were developed many
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81947b92e091d548a8c4e05e05f84e79
https://doi.org/10.1158/1538-7445.am2017-70
https://doi.org/10.1158/1538-7445.am2017-70
Autor:
Svetlana O. Doronina, Haley Neff-LaFord, Martha Anderson, Jocelyn R. Setter, Joshua H. Hunter, Mechthild Jonas, Robert P. Lyon, Tim D. Bovee, Patrick J. Burke, Peter D. Senter
Publikováno v:
Nature biotechnology. 33(7)
The in vitro potency of antibody-drug conjugates (ADCs) increases with the drug-to-antibody ratio (DAR); however, ADC plasma clearance also increases with DAR, reducing exposure and in vivo efficacy. Here we show that accelerated clearance arises fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c42fd52d5f1814493a6a88e8cbce0847
https://pubmed.ncbi.nlm.nih.gov/26076429
https://pubmed.ncbi.nlm.nih.gov/26076429
Publikováno v:
Cancer Research. 76:4994-4994
SEA-CD40 is a non-fucosylated, humanized IgG1 monoclonal antibody directed against human CD40, a co-stimulatory receptor of the TNF receptor superfamily. The consequence of enhanced SEA-CD40/FcγRIIIa binding is potent immune stimulatory activity. CD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a604ccd902c8c76103a53853452e78d
https://doi.org/10.1158/1538-7445.am2016-4994
https://doi.org/10.1158/1538-7445.am2016-4994